According to Zacks, “Alexion is a biopharmaceutical company focused on the development of treatments targeting ultra-rare disorders. The company is viewing Strensiq as the new growth driver in 2016 and beyond. This eventually should reduce the company’s dependence on a single product, Soliris, for growth. In fact, the company expects earnings to be driven by continued growth in Soliris, an increase in the number of patients on Strensiq and Kanuma beyond 2016, and the expansion of operating margins to 48–49% in 2018. Meanwhile, Alexion has quite a few candidates in its pipeline and also working on expanding Soliris’ label. Several pipeline-related news expected over the upcoming quarters could act as catalyst for the company. However, Alexion expects Soliris revenues in 2016 to be hampered by increased macroeconomic weakness in Latin America. Moreover, Alexion had lowered its earnings outlook for 2016 due to a higher tax rate.”
A number of other research analysts also recently commented on ALXN. Vetr downgraded Alexion Pharmaceuticals from a strong-buy rating to a strong sell rating and set a $107.00 target price on the stock. in a research note on Thursday, September 22nd. Piper Jaffray Cos. restated an overweight rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 16th. Morgan Stanley restated an overweight rating on shares of Alexion Pharmaceuticals in a research note on Wednesday, June 29th. Royal Bank Of Canada initiated coverage on Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They issued an outperform rating and a $188.00 target price on the stock. Finally, Citigroup Inc. upgraded Alexion Pharmaceuticals from a neutral rating to a buy rating and set a $154.00 target price on the stock in a research note on Monday, June 27th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $178.32.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.94% during trading on Tuesday, hitting $123.53. The stock had a trading volume of 481,133 shares. The firm has a market cap of $27.70 billion, a price-to-earnings ratio of 310.38 and a beta of 1.08. Alexion Pharmaceuticals has a 1-year low of $110.56 and a 1-year high of $193.45. The firm’s 50 day moving average is $130.16 and its 200 day moving average is $135.38.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The business had revenue of $753 million for the quarter, compared to analysts’ expectations of $743.18 million. During the same quarter in the prior year, the firm posted $1.44 EPS. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. On average, analysts anticipate that Alexion Pharmaceuticals will post $4.64 earnings per share for the current year.
In other Alexion Pharmaceuticals news, CFO Vikas Sinha sold 277 shares of the stock in a transaction on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $37,987.78. Following the transaction, the chief financial officer now directly owns 178,463 shares in the company, valued at approximately $24,474,415.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David Hallal sold 332 shares of the stock in a transaction on Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $45,530.48. Following the completion of the transaction, the chief executive officer now owns 189,266 shares in the company, valued at $25,955,939.24. The disclosure for this sale can be found here. Corporate insiders own 4.41% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALXN. Bank of Montreal Can bought a new position in Alexion Pharmaceuticals during the second quarter worth $34,314,000. Legal & General Group Plc increased its position in Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock worth $128,153,000 after buying an additional 35,267 shares during the period. Gateway Investment Advisers LLC increased its position in Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares during the period. Strs Ohio increased its position in Alexion Pharmaceuticals by 10.4% in the second quarter. Strs Ohio now owns 560,109 shares of the biopharmaceutical company’s stock worth $65,398,000 after buying an additional 52,710 shares during the period. Finally, Brown Advisory Inc. increased its position in Alexion Pharmaceuticals by 23.6% in the second quarter. Brown Advisory Inc. now owns 3,047,631 shares of the biopharmaceutical company’s stock worth $355,841,000 after buying an additional 581,703 shares during the period. Hedge funds and other institutional investors own 96.34% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.